Eurofins Genomics U.S., together with its subsidiary BlueHeron Biotechnology, has launched a series of SARS-CoV-2 plasmid DNA controls that can be used to detect the presence of the SARS-CoV-2 virus. They are intended to be used for R&D and IVD diagnostic applications.

Eurofins Genomics U.S. offers three different COVID-19 controls targeting key segments of the 30,000 base SARS-CoV-2 genome. One of the positive controls, CVGP, covers a wide swath of the sequence so that users can set up multiple reactions under a single control. Eurofins Genomics U.S. is able to produce and ship the plasmid control within one day.

The company has also ramped up production of reverse transcription quantitative polymerase chain reaction (qPCR RT) dual-labeled probes and primers for commercial and molecular diagnostic companies producing their own test kits. Eurofins Genomics U.S. has been able to meet demand and delivery timelines due to its logistical position in a major courier hub as well as its synthesis technology. On average, Eurofins Genomics U.S. ships out qPCR assay panels in three days.

All material for SARS-CoV-2, both the qPCR RT probes and plasmid controls, are produced under ISO 13485 and ISO 9001 for IVD products. The company’s experience partnering with IVD kit producers in the past has allowed them to respond to the spike in demand for test kits.